News >

Blackwell Hopeful New Agents Will Advance HER2+ Breast Cancer Care

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 24, 2016

Kimberly L. Blackwell, MD

Kimberly L. Blackwell, MD

Although the first- and second-line settings for patients with HER2-positive breast cancer are fairly standardized with pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1; Kadcyla) regimens, respectively, ongoing research continues to refine third-line care and beyond, according to Kimberly Blackwell, MD. 

The phase III NALA study, for example, is exploring the small molecule inhibitor neratinib in combination with capecitabine compared with capecitabine plus lapatinib (Tykerb) in patients with HER2-positive metastatic breast cancer who have received 2 or more prior HER2-directed regimens (NCT01808573).

The safety and tolerability of another small molecule inhibitor, ONT-380, plus capecitabine, trastuzumab (Herceptin), or both, is being investigated in an ongoing phase Ib study (NCT02025192) in patients with HER2+ metastatic breast cancer who have previously received trastuzumab and T-DM1 (for those eligible).

In an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer, Kimberly L. Blackwell, MD, a medical oncologist at Duke Cancer Institute, discussed the latest therapeutic developments for patients with HER2-positive breast cancer while providing insight on the hurdles that still remain.

OncLive: What HER2-positive breast cancer advancements did you highlight during this meeting?

Blackwell: In the area of HER2-positive breast cancer, it’s not only exciting but we have a lot of data that help drive decisions for helping our patients facing HER2-positive disease. I reviewed the state of the science in the treatment of patients with HER2-positive breast cancer. We have data now incorporating 3 novel HER2-targeted agents, including pertuzumab, T-DM1, and lapatinib. In each of these, we now have data that drives the orderly fashion: pertuzumab in first-line, T-DM1 in second-line, and small molecular inhibitors—lapatinib being one of them— in combination with capecitabine in third-line.

I also stressed the importance of continuing HER2-targeted agents—to not ever let your foot off of the brake when it comes to treating HER2-positive breast cancer.

Finally, I covered topics about exciting drugs in this area, and they include the novel small molecule inhibitors neratinib and a drug known as ONT-380, which is a pure HER2 small molecule inhibitor. We talked about HER2-directed liposomal chemotherapies, so there are a number of those being studied in clinical trials.

What I am particularly excited about is these super-charged versions of trastuzumab. These are antibodies that not only bind to HER2, but also really rev up the immune system. Those are all promising approaches to the treatment of HER2-positive breast cancer.

The FDA recently accepted a new drug application for neratinib. What potential could that agent have if it is approved?

We are all kind of awaiting the data that we don’t yet have on the use of neratinib in the metastatic arena. The strongest data for the activity of neratinib is in the early-stage setting, which is utilizing it after patients have finished 1 year of adjuvant trastuzumab.

With 5 years of follow-up, data show that it offers a significant improvement in invasive disease-free survival. This is if women complete 1 year of trastuzumab—and they are without evidence of disease—they then take 1 year of the small molecule pill known as neratinib. If it gets approved, the reality is that it will become a new standard of care. Women who are facing early-stage, HER2-positive breast cancer will complete 1 year of trastuzumab and then go on to receive 1 year of neratinib, once the regulatory approvals are made available.

The other data that we are awaiting in this space is the study known as APHINITY, and that is a study looking at adding pertuzumab in the first year on top of trastuzumab. The results of APHINITY and the results of the neratinib study—known as ExteNET—are independent results. If APHINITY is a positive study, I will still be offering patients neratinib after that 1 year of trastuzumab. What do we call that—the year 2, HER2 blockade? We are all very excited about it. The data now, with 5 years of follow-up, really looks like adding a year of neratinib after 1 year of trastuzumab helps prevent disease recurrence. When it becomes available, I will feel obligated to discuss it with my patients.

In your presentation, you discussed the CLEOPATRA and MARIANNE studies. What remains so impactful about these trials?

CLEOPATRA was important because adding pertuzumab really impacted overall survival. However, it didn’t make a significant contribution in terms of toxicity, which we worry about in an incurable metastatic setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x